(Bonus Episode) GLP-1: Please Start Low and Go Slow

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

(Bonus Episode) GLP-1: Please Start Low and Go Slow

Ascolta gratuitamente

Vedi i dettagli del titolo

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

Everyone’s suddenly “not hungry,” and we have questions. In this episode, we break down GLP-1 medications, the myths, the side effects nobody posts about, and why “start low and go slow” is not a suggestion — it’s a lifestyle.ReferencesAbu-Nejim, H. (2025). Current perspectives on GLP-1 receptor agonists in contemporary therapeutics. Journal of Clinical Medicine, 14(3), 455–468. https://pmc.ncbi.nlm.nih.gov/articles/PMC12511252/Advisory Board. (2026, January 12). The biggest health trends in 2026. https://www.advisory.com/daily-briefing/2026/01/12/health-trendsAssociated Press. (2026, January 14). Food companies target users of weight-loss drugs with “GLP-1 friendly” labels. https://apnews.com/article/5bb5dfaae3778b1968c1793326e8ba73IQVIA. (2026, January). Outlook for obesity in 2026: From consolidation to innovation. https://www.iqvia.com/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026Moiz, A. (2025). The expanding role of GLP-1 receptor agonists. Frontiers in Endocrinology, 16, 112233. https://pmc.ncbi.nlm.nih.gov/articles/PMC12303005/Reiss, A. B. (2025). Weight reduction with GLP-1 agonists and paths for future obesity therapies. International Journal of Obesity, 49(2), 215–224. https://pmc.ncbi.nlm.nih.gov/articles/PMC11940170/Reuters. (2026, January 7). Study finds weight and health issues return after stopping obesity drugs. https://www.reuters.com/business/healthcare-pharmaceuticals/less-than-two-years-after-stopping-obesity-drugs-weight-health-issues-return-2026-01-07/Reuters. (2026, January 14). AbbVie plans to build out its presence in obesity market. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-plans-build-out-its-presence-obesity-market-2026-01-14/Trujillo, J. M., & Nuffer, W. (2021). GLP-1 receptor agonists: An updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 12, 1–16. https://pmc.ncbi.nlm.nih.gov/articles/PMC7953228/U.S. News & World Report. (2026, January 6). GLP-1 ranks as No. 1 health trend for 2026. https://www.foodbusinessnews.net/articles/29573-glp-1-ranks-as-no-1-health-trend-for-2026World Health Organization. (2025, December 1). WHO issues global guideline on the use of GLP-1 medicines in treating obesity. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity#NurseChatDiaries#GLP1#StartLowGoSlow#HealthPodcast#HealthcareTalk#WeightLossMyths#MedicalHumor#HealthEducation#NurseLife#WellnessWithoutJudgment#ozempic

Ancora nessuna recensione